Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

397 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
Schöffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S, Lacombe D, Baron B, Herold M, Zwierzina H, Wilhelm-Ogunbiyi K, Lentzen H, Twelves C; European Organization for Research and Treatment of Cancer New Drug Development Group. Schöffski P, et al. Among authors: baron b. Ann Oncol. 2004 Dec;15(12):1816-24. doi: 10.1093/annonc/mdh469. Ann Oncol. 2004. PMID: 15550588 Free article. Clinical Trial.
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.
van den Bent MJ, Grisold W, Frappaz D, Stupp R, Desir JP, Lesimple T, Dittrich C, de Jonge MJ, Brandes A, Frenay M, Carpentier AF, Chollet P, Oliveira J, Baron B, Lacombe D, Schuessler M, Fumoleau P; European Organization for Research and Treatment of Cancer New Drug Development Group; European Organization for Research and Treatment of Cancer Brain Tumor Group. van den Bent MJ, et al. Among authors: baron b. Ann Oncol. 2003 Dec;14(12):1732-4. doi: 10.1093/annonc/mdg491. Ann Oncol. 2003. PMID: 14630677 Free article. Clinical Trial.
Phase II study of E7070 in patients with metastatic melanoma.
Smyth JF, Aamdal S, Awada A, Dittrich C, Caponigro F, Schöffski P, Gore M, Lesimple T, Djurasinovic N, Baron B, Ravic M, Fumoleau P, Punt CJ; EORTC New Drug Development and Melanoma Groups. Smyth JF, et al. Among authors: baron b. Ann Oncol. 2005 Jan;16(1):158-61. doi: 10.1093/annonc/mdi016. Ann Oncol. 2005. PMID: 15598954 Free article. Clinical Trial.
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.
Giaccone G, Smit EF, de Jonge M, Dansin E, Briasoulis E, Ardizzoni A, Douillard JY, Spaeth D, Lacombe D, Baron B, Bachmann P, Fumoleau P; EORTC-New Drug Development Group. Giaccone G, et al. Among authors: baron b. Eur J Cancer. 2004 Mar;40(5):667-72. doi: 10.1016/j.ejca.2003.10.027. Eur J Cancer. 2004. PMID: 15010066 Clinical Trial.
Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Köhne CH, Wils J, Lorenz M, Schöffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Rückle H, Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ; European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. Köhne CH, et al. Among authors: baron b. J Clin Oncol. 2003 Oct 15;21(20):3721-8. doi: 10.1200/JCO.2003.11.122. Epub 2003 Sep 8. J Clin Oncol. 2003. PMID: 12963704 Clinical Trial.
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.
Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheel S, Hecker H. Köhne CH, et al. Among authors: baron b. Ann Oncol. 2002 Feb;13(2):308-17. doi: 10.1093/annonc/mdf034. Ann Oncol. 2002. PMID: 11886010 Free article. Clinical Trial.
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.
de Jonge MJ, Droz JP, Paz-Ares L, van Oosterom AT, de Wit R, Chollet P, Baron B, Lacombe D, Mettinger K, Fumoleau P; EORTC-New Drug Development Group/New Drug Development Program. de Jonge MJ, et al. Among authors: baron b. Invest New Drugs. 2004 Aug;22(3):329-33. doi: 10.1023/B:DRUG.0000026260.24275.02. Invest New Drugs. 2004. PMID: 15122081 Clinical Trial.
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
Duffaud F, Borner M, Chollet P, Vermorken JB, Bloch J, Degardin M, Rolland F, Dittrich C, Baron B, Lacombe D, Fumoleau P; EORTC-New Drug Development Group/New Drug Development Program. Duffaud F, et al. Among authors: baron b. Eur J Cancer. 2004 Dec;40(18):2748-52. doi: 10.1016/j.ejca.2004.08.024. Eur J Cancer. 2004. PMID: 15571957 Clinical Trial.
397 results